Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Rennes University Hospital
With
Secondary purposes are : * To confirm the presence of plasma soluble form of PD-L1 in others malignancies * To study surface expression of PD-L1 on circulating tumour cells with multiparameter fow cytometry and Veridex® technology in DLBCL and metastatic breast cancer patients * To study surface expression of PD-L1 on circulating endothelial cells in DLBCL, Hodgkin lymphoma and metastatic breast cancer patients (subpart ended in late 2012) * To study surface expression of PD-L1 on different types of leukocytes (monocytes, B and T lymphocytes) * To separate circulating tumour cells expressing PD-L1 by immunomagnetic or Cell-sorting method * To develop ELISPOT technique to study the release of soluble PD-L1 in culture supernatants of selected cells (subpart ended mid 2013) * to evaluate the correlation between the expression of PD-L1 in the plasma and \*) the expression of PD-L1 in the tumor, \*\*) the expression of PD-L1 and other molecules in the bronchoalveolar liquid (whenever available from routine) in non-small cell lung cancer * to evaluate the response to treatment according to plasma PD-L1 expression in non-small cell lung cancer * to evaluate the susceptibility to develop a disease according to the single nucleotide polymorphisms of the PD-L1 gene in DLBCL and non-small cell lung cancer * Constitution of the different cohorts and collection of samples Main cohort : de novo DLBCL at diagnosis Secondary cohorts: Hodgkin's lymphoma, metastatic breast cancer, non small cell lung cancer Control cohorts : healthy volunteers (blood donors), patients with immune thrombocytopenia (ITP) * Quantification of plasma soluble PD-L1 in the different cohorts
Age
18–75
Sex
ALL
Healthy volunteers
Accepted